Management ChangeJun 23, 2026, 08:37 AM
Calidi Biotherapeutics Appoints Dr. Corazon Sanders to Board
AI Summary
Calidi Biotherapeutics, Inc. announced the appointment of Dr. Corazon Sanders to its Board of Directors as a Class III director, effective June 17, 2026. Dr. Sanders, a biotechnology executive with over 30 years of experience, will also serve on the Audit Committee. Concurrently, the Board increased its size from five to six members, and Scott Leftwich was removed from the Audit Committee, though he remains a board member. The company issued a press release on June 23, 2026, to announce this appointment.
Key Highlights
- Calidi Biotherapeutics appointed Dr. Corazon Sanders as a Class III director, effective June 17, 2026.
- Dr. Sanders' term as director will expire at the Company's 2029 annual meeting of stockholders.
- She was also appointed to serve as a member of the Board's Audit Committee.
- The Board increased its size from five to six members by adding a Class III director.
- Scott Leftwich was removed from the Audit Committee but remains a member of the Board.
- Dr. Sanders brings over 30 years of global leadership experience in drug development.
- She previously held senior executive positions at Juno Therapeutics and Genentech/Roche.
- Dr. Sanders currently serves on the boards of Ultragenyx Pharmaceutical Inc. and Legend Biotech Inc.
Price Impact
More from CLDI